Smart Buying Tips,azelaprag demonstrated significant cardioprotective effects

The bge 105 peptide, also known as azelaprag, is emerging as a significant therapeutic agent with the potential to address critical health challenges related to aging and metabolic disease. Developed by BioAge Labs, this compound is a potent APJ agonist, meaning it activates the apelin receptor (APJR). This mechanism is central to its observed effects on muscle health and body composition.

Understanding BGE 105 Peptide and its Mechanism of Action

BGE-105 is a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. It mimics the activity of apelin, a naturally occurring peptide that is released during exercise and is known to improve metabolic and muscle function. By activating the APJ receptor, azelaprag (formerly BGE-105) influences a range of physiological processes. Preclinical data have indicated that azelaprag can improve muscle regeneration and decrease muscle atrophy. Studies involving immobilized aged mice demonstrated that oral dosing with BGE-105 significantly reduced muscle atrophy compared to controls. Further research has shown that daily oral administration of BGE-105 for 7 days suppressed circulating levels of age-related proinflammatory cytokines and increased levels of BDNF in the brain, suggesting broader neuroprotective and anti-inflammatory benefits.

Clinical Development and Findings

BioAge Labs has been actively investigating the therapeutic potential of BGE-105 through various clinical trials. In a Phase 1b clinical trial evaluating muscle atrophy in older volunteers at bed rest, BGE-105 demonstrated positive topline results. Specifically, findings from this study showed that treatment with BGE-105 demonstrated a 100% improvement in thigh circumference in volunteers aged 65 years and older. This is a significant indicator of its ability to combat muscle loss associated with aging. Furthermore, BGE-105's protective effect on muscle atrophy has been a key focus, with early data suggesting it can protect against muscle wasting.

The development of BGE-105 is targeting acute muscle atrophy and chronic muscle loss, with the ultimate goal of improving healthspan. BioAge believes this peptide has the potential to address multiple severe indications driven by muscle aging, from acute hospital settings to chronic conditions.

BGE-105 in Obesity and Cardiometabolic Disease

Beyond muscle health, BGE-105 is also being explored for its role in treating obesity and related cardiometabolic conditions. BioAge Labs has announced plans to launch a Phase II trial of azelaprag (BGE-105) in combination with tirzepatide to treat individuals with obesity. Preclinical data from the co-administration of azelaprag with tirzepatide showed that it significantly increases total weight loss and improves body composition compared to tirzepatide alone. This synergistic effect highlights the potential of BGE-105 in enhancing weight management strategies.

Moreover, azelaprag demonstrated significant cardioprotective effects in a model of heart failure with preserved ejection fraction (HFpEF) associated with obesity and hypertension, while also promoting substantial weight loss. This suggests that BGE-105 is designed to combat muscle aging and may offer multifaceted benefits for individuals with metabolic disorders.

Regulatory and Development Milestones

BioAge has a strategic partnership with Amgen, having licensed the drug from them. Initially known as AMG 986, the compound was rebranded as BGE-105 and later as azelaprag. Phase 1 clinical trials were completed in 2019, involving 198 subjects, and demonstrated the compound's safety profile. BioAge is collecting muscle biomarker data from ongoing trials to inform further Phase 2 development.

While trials are progressing, it's important to note that clinical development can face challenges. In December 2024, BioAge announced the halting of the Phase II STRIDES trial of the obesity drug, indicating that such programs are subject to rigorous evaluation and potential setbacks. Nonetheless, the ongoing research into BGE-105 and its potential applications in muscle aging, obesity, and cardiometabolic disease underscores its significance in the field of aging research and therapeutic innovation. The ongoing exploration of BGE and its specific designation as 105 continues to reveal its broad therapeutic promise.